Trial reportKidney3602026
Telemedicine versus Face-to-Face Follow-Up in Post-Acute Kidney Injury Survivors: A Pilot Randomized Controlled Trial.
Trial report in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
key pointsThis is the first randomized controlled trial to evaluate the feasibility of telemedicine specifically in the follow-up care of post-AKI survivors. Telemedicine proved practical by reducing travel and waiting times while maintaining high patient satisfaction and clinical monitoring quality. Less frequent serum creatinine measurements in the telemedicine group highlight a potential feasibility limitation for virtual follow-up.
backgroundRegular postdischarge follow-up with a nephrologist is recommended for post-AKI survivors; however, accessibility barriers, particularly among patients with multiple comorbidities or those living in remote areas, often limit continuity of care. Telemedicine offers a potential solution, but evidence in post-AKI populations remains limited.
methodsThis single-center, open-label, randomized controlled trial was conducted at Thammasat University Hospital, Thailand. Adults who survived hospitalization with stages 2-3 AKI and lived ≥15 km from the hospital were randomly assigned to telemedicine follow-up using the secure Thammasat University Hospital Telemed application or conventional face-to-face follow-up for 6 months. The primary outcome was feasibility, assessed using three process indicators: ( 1 ) follow-up adherence, ( 2 ) serum creatinine measurement, and ( 3 ) BP measurement. Secondary outcomes included clinical (mortality, readmission, CKD progression, recurrent AKI, and BP control) and patient-centered outcomes (satisfaction, waiting time, travel time, and travel cost).
resultsA total of 58 post-AKI patients were enrolled, with 29 assigned to the conventional face-to-face follow-up group and 29 to the telemedicine follow-up group. The mean age was 65.2±14.3 years, and 57% were male. At 6 months, follow-up adherence, the key feasibility indicator, was similar between the telemedicine and face-to-face groups (90% versus 90%, P = 1.00). BP measurement rates were also comparable (92% versus 100%, P = 0.15). However, serum creatinine measurement was significantly lower in the telemedicine group (58% versus 100%, P < 0.001). Patients in the telemedicine group had significantly lower travel costs, shorter travel time, and shorter waiting time. Patient satisfaction remained high in both groups (9.2±0.8 versus 9.1±0.7, P = 0.46).
conclusionsTelemedicine follow-up for post-AKI survivors achieved follow-up adherence comparable with conventional face-to-face care, supporting its feasibility. However, lower rates of laboratory monitoring highlight an important implementation limitation of virtual follow-up. In addition, telemedicine reduced travel and waiting times while maintaining high patient satisfaction. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Thai Clinical Trials Registry, TCTR20240928002 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.